Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acyclovir influence on graft versus host disease

R Saral1

  • 1Emory University School of Medicine, Department of Medicine, Atlanta, Georgia 30322.

Journal of Medical Virology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy.

Blood·1997
Same author

FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation.

Blood·1996
Same author

Association of busulfan area under the curve with veno-occlusive disease following BMT.

Bone marrow transplantation·1996
Same author

American Society for Blood and Marrow Transplantation guidelines for training.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·1995
Same author

CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1.

Blood·1995
Same author

Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification.

Journal of clinical microbiology·1995

Allogeneic bone marrow transplantation offers a life-saving therapy for malignant and certain nonmalignant diseases. This procedure uses external bone marrow to restore function after high-dose chemotherapy or irradiation, with success rates varying by disease and stage.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Allogeneic bone marrow transplantation (BMT) is a long-standing therapy for malignant diseases.
  • It involves high-dose chemotherapy and/or irradiation to eradicate cancer cells.
  • External bone marrow provides a rescue for damaged bone marrow function.

Purpose of the Study:

  • To review the established use and expanding applications of allogeneic bone marrow transplantation.
  • To highlight its efficacy in treating hematologic malignancies and certain nonmalignant conditions.
  • To mention advances in supportive care, such as antiviral prophylaxis.

Main Methods:

  • Review of established allogeneic bone marrow transplantation protocols.
  • Analysis of success rates in various hematologic malignancies and nonmalignant diseases.

Related Experiment Videos

  • Inclusion of data on supportive care advancements, including antiviral therapies.

    • Main Results:

    • Allogeneic BMT demonstrates significant success in treating acute and chronic leukemia, with 5-year disease-free survival rates of 30-80%.
    • The procedure is also effective for nonmalignant conditions like severe aplastic anemia and genetic disorders.
    • Effective antiviral therapies (e.g., acyclovir) improve outcomes by managing infections like HSV, CMV, and VZV.

    Conclusions:

    • Allogeneic bone marrow transplantation remains a critical therapeutic option for a range of hematologic malignancies.
    • Its application is broadening with the use of less-matched donors and successful treatment of nonmalignant diseases.
    • Advances in supportive care, particularly antiviral prophylaxis, enhance patient survival and treatment success.